Collier DJ, et al. – Investigators assessed the efficacy and safety of adding chlortalidone (CLD) to azilsartan medoxomil (AZL-M) monotherapy for the treatment of hypertensive patients uncontrolled on AZL-M alone. They administered 40-mg AZL-M monotherapy to patients with grade 2-3 essential hypertension who also had a post-placebo mean clinic systolic blood pressure (SBP) level of 160-190 mm Hg and a 24-hour SBP level of 140-175 mm Hg (measured by ambulatory blood pressure monitoring), for 4 weeks. They then randomized non-responders to 8 weeks of double-blind treatment with AZL-M 40 mg, AZL-M/CLD 40/25 mg, or AZL-M/CLD 40/12.5 mg. Findings revealed that, AZL-M in combination with CLD was efficacious and demonstrated good tolerability in hypertensive patients not achieving target BP levels with AZL-M monotherapy.